GlassScriptPhysician profile
Ashley D Hill
NPI 1215348305
$4,326.20
in general payments reported to CMS, 2019-2025
44 companies · $428 in 2025
The $428 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $132 · 2021: $724 · 2022: $978 · 2023: $705 · 2024: $758 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $1,002.00 | 2020-2024 | Ova1 |
| Biogen, INC. | $425.19 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $396.59 | 2019-2024 | |
| Astellas Pharma US INC | $278.60 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $258.71 | 2021-2024 | |
| Organon LLC | $181.14 | 2022-2025 | Nexplanon |
| Amgen INC. | $176.09 | 2019-2023 | Prolia, Evenity |
| Pfizer INC. | $164.84 | 2022-2025 | |
| Shield Therapeutics INC | $129.82 | 2023-2025 | Accrufer |
| Exeltis, USA INC. | $111.75 | 2021-2023 | Slynd |
| Daiichi Sankyo INC. | $109.08 | 2019-2024 | Injectafer |
| Channel Medsystems, INC. | $106.42 | 2023 | |
| Sumitomo Pharma America, INC. | $100.24 | 2023-2025 | Myfembree, Gemtesa |
| Novo Nordisk INC | $93.36 | 2019-2023 | Wegovy |
| Dysis Medical, INC. | $69.00 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.